Advertisement

Immune Dysregulation Diseases

  • Shinsaku Imashuku
  • Melinda Erdős
  • Waleed Al-Herz
  • Mohammad Hassan Bemanian
  • Hirokazu Kanegane
  • László Maródi
  • Payam Mohammadinejad
  • Sergio D. Rosenzweig
  • Asghar Aghamohammadi
Chapter

Abstract

The main task of immune system is to protect the body against infections. When an antigen is recognized as a nonself by the immune system, a highly dynamic cascade of reactions will begin which includes both innate and adaptive immune responses. These mechanisms should be firmly controlled because exaggerated response to foreign antigens and/or improper response against self-antigens can result in autoimmunity. Various cells and mediator molecules are involved in the regulation of immune system. The complexity of this system makes it prone to many genetic defects resulting in increased susceptibility to infections and/or autoimmune disorders.

Keywords

Infectious Mononucleosis Hair Shaft Oculocutaneous Albinism Familial Hemophagocytic Lymphohistiocytosis SH2D1A Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Torgerson TR (2008) Immune dysregulation in primary immunodeficiency disorders. Immunol Allergy Clin North Am 28(2):315–327, viii–ixPubMedCrossRefGoogle Scholar
  2. 2.
    Halonen M, Eskelin P, Myhre AG, Perheentupa J, Husebye ES, Kampe O, Rorsman F, Peltonen L, Ulmanen I, Partanen J (2002) AIRE mutations and human leukocyte antigen genotypes as determinants of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy phenotype. J Clin Endocrinol Metab 87(6):2568–2574PubMedCrossRefGoogle Scholar
  3. 3.
    Torgerson TR, Ochs HD (2007) Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol 120(4):744–750, quiz 751–742PubMedCrossRefGoogle Scholar
  4.  4.
    Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, Henter JI, Bennett M, Fischer A, de Basile Saint G, Kumar V (1999) Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286(5446):1957–1959PubMedCrossRefGoogle Scholar
  5.  5.
    Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, Dumont C, Lambert N, Ouachee-Chardin M, Chedeville G, Tamary H, Minard-Colin V, Vilmer E, Blanche S, Le Deist F, Fischer A, de Basile Saint G (2003) Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115(4):461–473PubMedCrossRefGoogle Scholar
  6.  6.
    Zur Stadt U, Schmidt S, Kasper B, Beutel K, Diler AS, Henter JI, Kabisch H, Schneppenheim R, Nurnberg P, Janka G, Hennies HC (2005) Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet 14(6):827–834PubMedCrossRefGoogle Scholar
  7.  7.
    Zhang K, Jordan MB, Marsh RA, Johnson JA, Kissell D, Meller J, Villanueva J, Risma KA, Wei Q, Klein PS, Filipovich AH (2011) Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial hemophagocytic lymphohistiocytosis. Blood 118(22):5794–8, Epub 2011 Aug 31PubMedCrossRefGoogle Scholar
  8.  8.
    Ward DM, Shiflett SL, Kaplan J (2002) Chediak-Higashi syndrome: a clinical and molecular view of a rare lysosomal storage disorder. Curr Mol Med 2(5):469–477PubMedCrossRefGoogle Scholar
  9.  9.
    Menasche G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, Wulffraat N, Bianchi D, Fischer A, Le Deist F, de Basile Saint G (2000) Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet 25(2):173–176PubMedCrossRefGoogle Scholar
  10. 10.
    Enders A, Zieger B, Schwarz K, Yoshimi A, Speckmann C, Knoepfle EM, Kontny U, Muller C, Nurden A, Rohr J, Henschen M, Pannicke U, Niemeyer C, Nurden P, Ehl S (2006) Lethal hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type II. Blood 108(1):81–87PubMedCrossRefGoogle Scholar
  11. 11.
    Neeft M, Wieffer M, de Jong AS, Negroiu G, Metz CH, van Loon A, Griffith J, Krijgsveld J, Wulffraat N, Koch H, Heck AJ, Brose N, Kleijmeer M, van der Sluijs P (2005) Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol Biol Cell 16(2):731–741PubMedCrossRefGoogle Scholar
  12. 12.
    Menager MM, Menasche G, Romao M, Knapnougel P, Ho CH, Garfa M, Raposo G, Feldmann J, Fischer A, de Basile Saint G (2007) Secretory cytotoxic granule maturation and exocytosis require the effector protein hMunc13-4. Nat Immunol 8(3):257–267PubMedCrossRefGoogle Scholar
  13. 13.
    Wei ML (2006) Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function. Pigment Cell Res 19(1):19–42PubMedCrossRefGoogle Scholar
  14. 14.
    Cullinane AR, Curry JA, Carmona-Rivera C, Summers CG, Ciccone C, Cardillo ND, Dorward H, Hess RA, White JG, Adams D, Huizing M, Gahl WA (2011) A BLOC-1 mutation screen reveals that PLDN is mutated in Hermansky-Pudlak syndrome type 9. Am J Hum Genet 88(6):778–787PubMedCrossRefGoogle Scholar
  15. 15.
    Bohn G, Welte K, Klein C (2007) Severe congenital neutropenia: new genes explain an old disease. Curr Opin Rheumatol 19(6):644–650PubMedCrossRefGoogle Scholar
  16. 16.
    Thielen N, Huizing M, Krabbe JG, White JG, Jansen TJ, Merle PA, Gahl WA, Zweegman S (2010) Hermansky-Pudlak syndrome: the importance of molecular subtyping. J Thromb Haemost 8(7):1643–1645PubMedCrossRefGoogle Scholar
  17. 17.
    Jung J, Bohn G, Allroth A, Boztug K, Brandes G, Sandrock I, Schaffer AA, Rathinam C, Kollner I, Beger C, Schilke R, Welte K, Grimbacher B, Klein C (2006) Identification of a homozygous deletion in the AP3B1 gene causing Hermansky-Pudlak syndrome, type 2. Blood 108(1):362–369PubMedCrossRefGoogle Scholar
  18. 18.
    Clark RH, Stinchcombe JC, Day A, Blott E, Booth S, Bossi G, Hamblin T, Davies EG, Griffiths GM (2003) Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat Immunol 4(11):1111–1120PubMedCrossRefGoogle Scholar
  19. 19.
    Fontana S, Parolini S, Vermi W, Booth S, Gallo F, Donini M, Benassi M, Gentili F, Ferrari D, Notarangelo LD, Cavadini P, Marcenaro E, Dusi S, Cassatella M, Facchetti F, Griffiths GM, Moretta A, Badolato R (2006) Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood 107(12):4857–4864PubMedCrossRefGoogle Scholar
  20. 20.
    Badolato R, Parolini S (2007) Novel insights from adaptor protein 3 complex deficiency. J Allergy Clin Immunol 120(4):735–741, quiz 742–743PubMedCrossRefGoogle Scholar
  21. 21.
    Rozenszajn LA, David EB, Sela SB (1977) Large granules and lysosomal fusion in human Chediak-Higashi white blood cells. Acta Haematol 57(5):279–289PubMedCrossRefGoogle Scholar
  22. 22.
    Rubin CM, Burke BA, McKenna RW, McClain KL, White JG, Nesbit ME Jr, Filipovich AH (1985) The accelerated phase of Chediak-Higashi syndrome. An expression of the virus-associated hemophagocytic syndrome? Cancer 56(3):524–530PubMedCrossRefGoogle Scholar
  23. 23.
    Trottestam H, Beutel K, Meeths M, Carlsen N, Heilmann C, Pasic S, Webb D, Hasle H, Henter JI (2009) Treatment of the X-linked lymphoproliferative, Griscelli and Chediak-Higashi syndromes by HLH directed therapy. Pediatr Blood Cancer 52(2):268–272PubMedCrossRefGoogle Scholar
  24. 24.
    Henter JI, Elinder G, Ost A (1991) Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol 18(1):29–33PubMedGoogle Scholar
  25. 25.
    Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, McClain K, Webb D, Winiarski J, Janka G (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131PubMedCrossRefGoogle Scholar
  26. 26.
    Imashuku S (2000) Advances in the management of hemophagocytic lymphohistiocytosis. Int J Hematol 72(1):1–11PubMedGoogle Scholar
  27. 27.
    Janka GE, Schneider EM (2004) Modern management of children with haemophagocytic lymphohistiocytosis. Br J Haematol 124(1):4–14PubMedCrossRefGoogle Scholar
  28. 28.
    Janka GE (2007) Hemophagocytic syndromes. Blood Rev 21(5):245–253PubMedCrossRefGoogle Scholar
  29. 29.
    Janka G, Imashuku S, Elinder G, Schneider M, Henter JI (1998) Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 12(2):435–444PubMedCrossRefGoogle Scholar
  30. 30.
    Ishii E, Ohga S, Imashuku S, Yasukawa M, Tsuda H, Miura I, Yamamoto K, Horiuchi H, Takada K, Ohshima K, Nakamura S, Kinukawa N, Oshimi K, Kawa K (2007) Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 86(1):58–65PubMedCrossRefGoogle Scholar
  31. 31.
    Cetica V, Pende D, Griffiths GM, Arico M (2010) Molecular basis of familial hemophagocytic lymphohistiocytosis. Haematologica 95(4):538–541PubMedCrossRefGoogle Scholar
  32. 32.
    Booth C, Gilmour KC, Veys P, Gennery AR, Slatter MA, Chapel H, Heath PT, Steward CG, Smith O, O’Meara A, Kerrigan H, Mahlaoui N, Cavazzana-Calvo M, Fischer A, Moshous D, Blanche S, Pachlopnick-Schmid J, Latour S, de Saint-Basile G, Albert M, Notheis G, Rieber N, Strahm B, Ritterbusch H, Lankester A, Hartwig NG, Meyts I, Plebani A, Soresina A, Finocchi A, Pignata C, Cirillo E, Bonanomi S, Peters C, Kalwak K, Pasic S, Sedlacek P, Jazbec J, Kanegane H, Nichols KE, Hanson IC, Kapoor N, Haddad E, Cowan M, Choo S, Smart J, Arkwright PD, Gaspar HB (2011) X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood 117(1):53–62PubMedCrossRefGoogle Scholar
  33. 33.
    Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH (2010) XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 116(7):1079–1082PubMedCrossRefGoogle Scholar
  34. 34.
    Ueda I, Ishii E, Morimoto A, Ohga S, Sako M, Imashuku S (2006) Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL). Pediatr Blood Cancer 46(4):482–488PubMedCrossRefGoogle Scholar
  35. 35.
    Marcenaro S, Gallo F, Martini S, Santoro A, Griffiths GM, Arico M, Moretta L, Pende D (2006) Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood 108(7):2316–2323PubMedCrossRefGoogle Scholar
  36. 36.
    Meeths M, Entesarian M, Al-Herz W, Chiang SC, Wood SM, Al-Ateeqi W, Almazan F, Boelens JJ, Hasle H, Ifversen M, Lund B, van den Berg JM, Gustafsson B, Hjelmqvist H, Nordenskjold M, Bryceson YT, Henter JI (2010) Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis type 5 patients with mutations in STXBP2. Blood 116(15):2635–2643PubMedCrossRefGoogle Scholar
  37. 37.
    Ueda I, Kurokawa Y, Koike K, Ito S, Sakata A, Matsumora T, Fukushima T, Morimoto A, Ishii E, Imashuku S (2007) Late-onset cases of familial hemophagocytic lymphohistiocytosis with missense perforin gene mutations. Am J Hematol 82(6):427–432PubMedCrossRefGoogle Scholar
  38. 38.
    Rudd E, Bryceson YT, Zheng C, Edner J, Wood SM, Ramme K, Gavhed S, Gurgey A, Hellebostad M, Bechensteen AG, Ljunggren HG, Fadeel B, Nordenskjold M, Henter JI (2008) Spectrum, and clinical and functional implications of UNC13D mutations in familial haemophagocytic lymphohistiocytosis. J Med Genet 45(3):134–141PubMedCrossRefGoogle Scholar
  39. 39.
    Bryceson YT, Rudd E, Zheng C, Edner J, Ma D, Wood SM, Bechensteen AG, Boelens JJ, Celkan T, Farah RA, Hultenby K, Winiarski J, Roche PA, Nordenskjold M, Henter JI, Long EO, Ljunggren HG (2007) Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood 110(6):1906–1915PubMedCrossRefGoogle Scholar
  40. 40.
    Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE (2011) Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol 127(6):1329–1341.e1322, quiz 1342–1343PubMedCrossRefGoogle Scholar
  41. 41.
    Gismondi A, Cifaldi L, Mazza C, Giliani S, Parolini S, Morrone S, Jacobelli J, Bandiera E, Notarangelo L, Santoni A (2004) Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood 104(2):436–443PubMedCrossRefGoogle Scholar
  42. 42.
    Argov S, Johnson DR, Collins M, Koren HS, Lipscomb H, Purtilo DT (1986) Defective natural killing activity but retention of lymphocyte-mediated antibody-dependent cellular cytotoxicity in patients with the X-linked lymphoproliferative syndrome. Cell Immunol 100(1):1–9PubMedCrossRefGoogle Scholar
  43. 43.
    Endt J, Eissmann P, Hoffmann SC, Meinke S, Giese T, Watzl C (2007) Modulation of 2B4 (CD244) activity and regulated SAP expression in human NK cells. Eur J Immunol 37(1):193–198PubMedCrossRefGoogle Scholar
  44. 44.
    Katz P, Zaytoun AM, Fauci AS (1982) Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay. J Clin Invest 69(6):1231–1238PubMedCrossRefGoogle Scholar
  45. 45.
    Eife R, Janka GE, Belohradsky BH, Holtmann H (1989) Natural killer cell function and interferon production in familial hemophagocytic lymphohistiocytosis. Pediatr Hematol Oncol 6(3):265–272PubMedCrossRefGoogle Scholar
  46. 46.
    Imashuku S, Hyakuna N, Funabiki T, Ikuta K, Sako M, Iwai A, Fukushima T, Kataoka S, Yabe M, Muramatsu K, Kohdera U, Nakadate H, Kitazawa K, Toyoda Y, Ishii E (2002) Low natural killer activity and central nervous system disease as a high-risk prognostic indicator in young patients with hemophagocytic lymphohistiocytosis. Cancer 94(11):3023–3031PubMedCrossRefGoogle Scholar
  47. 47.
    Horne A, Zheng C, Lorenz I, Lofstedt M, Montgomery SM, Janka G, Henter JI, Marion Schneider E (2005) Subtyping of natural killer cell cytotoxicity deficiencies in haemophagocytic lymphohistiocytosis provides therapeutic guidance. Br J Haematol 129(5):658–666PubMedCrossRefGoogle Scholar
  48. 48.
    Imashuku S (2002) Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Crit Rev Oncol Hematol 44(3):259–272PubMedCrossRefGoogle Scholar
  49. 49.
    Mischler M, Fleming GM, Shanley TP, Madden L, Levine J, Castle V, Filipovich AH, Cornell TT (2007) Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit. Pediatrics 119(5):e1212–1218PubMedCrossRefGoogle Scholar
  50. 50.
    Beutel K, Gross-Wieltsch U, Wiesel T, Stadt UZ, Janka G, Wagner HJ (2009) Infection of T lymphocytes in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children of non-Asian origin. Pediatr Blood Cancer 53(2):184–190PubMedCrossRefGoogle Scholar
  51. 51.
    Huck K, Feyen O, Niehues T, Ruschendorf F, Hubner N, Laws HJ, Telieps T, Knapp S, Wacker HH, Meindl A, Jumaa H, Borkhardt A (2009) Girls homozygous for an IL-2-inducible T cell kinase mutation that leads to protein deficiency develop fatal EBV-associated lymphoproliferation. J Clin Invest 119(5):1350–1358PubMedCrossRefGoogle Scholar
  52. 52.
    Okano M, Kawa K, Kimura H, Yachie A, Wakiguchi H, Maeda A, Imai S, Ohga S, Kanegane H, Tsuchiya S, Morio T, Mori M, Yokota S, Imashuku S (2005) Proposed guidelines for diagnosing chronic active Epstein-Barr virus infection. Am J Hematol 80(1):64–69PubMedCrossRefGoogle Scholar
  53. 53.
    Kasahara Y, Yachie A, Takei K, Kanegane C, Okada K, Ohta K, Seki H, Igarashi N, Maruhashi K, Katayama K, Katoh E, Terao G, Sakiyama Y, Koizumi S (2001) Differential cellular targets of Epstein-Barr virus (EBV) infection between acute EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Blood 98(6):1882–1888PubMedCrossRefGoogle Scholar
  54. 54.
    Yoshiyama M, Kounami S, Nakayama K, Aoyagi N, Yoshikawa N (2008) Clinical assessment of Mycoplasma pneumoniae-associated hemophagocytic lymphohistiocytosis. Pediatr Int 50(4):432–435PubMedCrossRefGoogle Scholar
  55. 55.
    Schwarzmeier JD (2002) A potentially fatal complication of Mycoplasma pneumoniae infection – the hemophagocytic syndrome. Respiration 69(1):14–15PubMedCrossRefGoogle Scholar
  56. 56.
    Rajagopala S, Dutta U, Chandra KS, Bhatia P, Varma N, Kochhar R (2008) Visceral leishmaniasis associated hemophagocytic lymphohistiocytosis – case report and systematic review. J Infect 56(5):381–388PubMedCrossRefGoogle Scholar
  57. 57.
    Kontopoulou T, Tsaousis G, Vaidakis E, Fanourgiakis P, Michalakeas E, Trigoni E, Samarkos M (2002) Hemophagocytic syndrome in association with visceral leishmaniasis. Am J Med 113(5):439–440PubMedCrossRefGoogle Scholar
  58. 58.
    Eliopoulos G, Vaiopoulos G, Kittas C, Fessas P (1992) Tuberculosis associated hemophagocytic syndrome complicated with severe bone marrow failure and disseminated intravascular coagulation. Nouv Rev Fr Hematol 34(3):273–276PubMedGoogle Scholar
  59. 59.
    Goto S, Aoike I, Shibasaki Y, Morita T, Miyazaki S, Shimizu T, Suzuki M (2001) A successfully treated case of disseminated tuberculosis-associated hemophagocytic syndrome and multiple organ dysfunction syndrome. Am J Kidney Dis 38(4):E19PubMedCrossRefGoogle Scholar
  60. 60.
    Imashuku S (2007) Systemic type Epstein-Barr virus-related lymphoproliferative diseases in children and young adults: challenges for pediatric hemato-oncologists and infectious disease specialists. Pediatr Hematol Oncol 24(8):563–568PubMedCrossRefGoogle Scholar
  61. 61.
    Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, Matsuyama T, Morishima T (1999) Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 37(1):132–136PubMedGoogle Scholar
  62. 62.
    Teramura T, Tabata Y, Yagi T, Morimoto A, Hibi S, Imashuku S (2002) Quantitative analysis of cell-free Epstein-Barr virus genome copy number in patients with EBV-associated hemophagocytic lymphohistiocytosis. Leuk Lymphoma 43(1):173–179PubMedCrossRefGoogle Scholar
  63. 63.
    Au WY, Pang A, Choy C, Chim CS, Kwong YL (2004) Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104(1):243–249PubMedCrossRefGoogle Scholar
  64. 64.
    Orentas RJ, Rospkopf SJ, Casper JT, Getts RC, Nilsen TW (1999) Detection of Epstein-Barr virus EBER sequence in post-transplant lymphoma patients with DNA dendrimers. J Virol Methods 77(2):153–163PubMedCrossRefGoogle Scholar
  65. 65.
    Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander AR, Bacher U (2008) EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 42(3):181–186PubMedCrossRefGoogle Scholar
  66. 66.
    Meijer E, Cornelissen JJ (2008) Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 15(6):576–585PubMedCrossRefGoogle Scholar
  67. 67.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Yegitbasi M, Reinke P, Kebelmann-Betzig C, Hauptmann K, Gross-Wieltsch U, Hetzer R, Berger F (2009) Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients. Pediatr Transplant 13(1):54–62PubMedCrossRefGoogle Scholar
  68. 68.
    Gross TG (2009) Treatment for Epstein-Barr virus-associated PTLD. Herpes 15(3):64–67PubMedGoogle Scholar
  69. 69.
    O’Sullivan CE, Peng R, Cole KS, Montelaro RC, Sturgeon T, Jenson HB, Ling PD (2002) Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART. J Med Virol 67(3):320–326PubMedCrossRefGoogle Scholar
  70. 70.
    Bekker V, Scherpbier H, Beld M, Piriou E, van Breda A, Lange J, van Leth F, Jurriaans S, Alders S, Wertheim-van Dillen P, van Baarle D, Kuijpers T (2006) Epstein-Barr virus infects B and non-B lymphocytes in HIV-1-infected children and adolescents. J Infect Dis 194(9):1323–1330PubMedCrossRefGoogle Scholar
  71. 71.
    Padeh S, Sharon N, Schiby G, Rechavi G, Passwell JH (1997) Hodgkin’s lymphoma in ­systemic onset juvenile rheumatoid arthritis after treatment with low dose methotrexate. J Rheumatol 24(10):2035–2037PubMedGoogle Scholar
  72. 72.
    Said JW (2007) Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol 14(3):189–194PubMedCrossRefGoogle Scholar
  73. 73.
    Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK (2008) Immunodeficiency-associated lymphomas. Blood Rev 22(5):261–281PubMedCrossRefGoogle Scholar
  74. 74.
    Cuneo A, Bigoni R, Rigolin GM, Roberti MG, Milani R, Bardi A, Minotto C, Agostini P, De Angeli C, Narducci MG, Sabbioni S, Russo G, Negrini M, Castoldi G (2000) Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin’s lymphoma: correlation with clinicobiologic features. J Clin Oncol 18(13):2607–2614PubMedGoogle Scholar
  75. 75.
    Seidemann K, Henze G, Beck JD, Sauerbrey A, Kuhl J, Mann G, Reiter A (2000) Non-Hodgkin’s lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol 11(Suppl 1):141–145PubMedCrossRefGoogle Scholar
  76. 76.
    Imashuku S, Miyagawa A, Chiyonobu T, Ishida H, Yoshihara T, Teramura T, Kuriyama K, Imamura T, Hibi S, Morimoto A, Todo S (2002) Epstein-Barr virus-associated T-lymphoproliferative disease with hemophagocytic syndrome, followed by fatal intestinal B lymphoma in a young adult female with WHIM syndrome. Warts, hypogammaglobulinemia, infections, and myelokathexis. Ann Hematol 81(8):470–473PubMedCrossRefGoogle Scholar
  77. 77.
    Balabanian K, Lagane B, Pablos JL, Laurent L, Planchenault T, Verola O, Lebbe C, Kerob D, Dupuy A, Hermine O, Nicolas JF, Latger-Cannard V, Bensoussan D, Bordigoni P, Baleux F, Le Deist F, Virelizier JL, Arenzana-Seisdedos F, Bachelerie F (2005) WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. Blood 105(6):2449–2457PubMedCrossRefGoogle Scholar
  78. 78.
    Chae KM, Ertle JO, Tharp MD (2001) B-cell lymphoma in a patient with WHIM syndrome. J Am Acad Dermatol 44(1):124–128PubMedCrossRefGoogle Scholar
  79. 79.
    Wallet-Faber N, Bodemer C, Blanche S, Delabesse E, Eschard C, Brousse N, Fraitag S (2008) Primary cutaneous Epstein-Barr virus-related lymphoproliferative disorders in 4 immunosuppressed children. J Am Acad Dermatol 58(1):74–80PubMedCrossRefGoogle Scholar
  80. 80.
    Modell V, Gee B, Lewis DB, Orange JS, Roifman CM, Routes JM, Sorensen RU, Notarangelo LD, Modell F (2011) Global study of primary immunodeficiency diseases (PI)-diagnosis, treatment, and economic impact: an updated report from the Jeffrey Modell Foundation. Immunol Res 51(1):61–70PubMedCrossRefGoogle Scholar
  81. 81.
    Phadke SR, Aggarwal S, Kumari N (2011) The expanding spectrum of Elejalde syndrome: overlap with other disorders of overgrowth. Clin Dysmorphol 20(2):98–101PubMedCrossRefGoogle Scholar
  82. 82.
    Cahali JB, Fernandez SA, Oliveira ZN, Machado MC, Valente NS, Sotto MN (2004) Elejalde syndrome: report of a case and review of the literature. Pediatr Dermatol 21(4):479–482PubMedCrossRefGoogle Scholar
  83. 83.
    de Vries E (2006) Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists. Clin Exp Immunol 145(2):204–214PubMedCrossRefGoogle Scholar
  84. 84.
    Fleisher TA (2007) Evaluation of suspected immunodeficiency. Adv Exp Med Biol 601:291–300PubMedCrossRefGoogle Scholar
  85. 85.
    Kharkar V, Pande S, Mahajan S, Dwiwedi R, Khopkar U (2007) Griscelli syndrome: a new phenotype with circumscribed pigment loss? Dermatol Online J 13(2):17PubMedGoogle Scholar
  86. 86.
    Rao S, Kar R, Saxena R (2009) Pseudo Chediak-Higashi anomaly in acute myelomonocytic leukemia. Indian J Pathol Microbiol 52(2):255–256PubMedCrossRefGoogle Scholar
  87. 87.
    Whaley BF (2011) Familial hemophagocytic lymphohistiocytosis in the neonate. Adv Neonatal Care 11(2):101–107PubMedCrossRefGoogle Scholar
  88. 88.
    Pastural E, Barrat FJ, Dufourcq-Lagelouse R, Certain S, Sanal O, Jabado N, Seger R, Griscelli C, Fischer A, de Basile Saint G (1997) Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat Genet 16(3):289–292PubMedCrossRefGoogle Scholar
  89. 89.
    Menasche G, Ho CH, Sanal O, Feldmann J, Tezcan I, Ersoy F, Houdusse A, Fischer A, de Basile Saint G (2003) Griscelli syndrome restricted to hypopigmentation results from a ­melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1). J Clin Invest 112(3):450–456PubMedGoogle Scholar
  90. 90.
    Janka G, zur Stadt U. Familial and acquired hemophagocytic lymphohistiocytosis. Hematology Am Soc Hematol Educ Program. 2005:82–8Google Scholar
  91. 91.
    Griscelli C, Prunieras M (1978) Pigment dilution and immunodeficiency: a new syndrome. Int J Dermatol 17(10):788–791PubMedCrossRefGoogle Scholar
  92. 92.
    Sneller MC, Dale JK, Straus SE (2003) Autoimmune lymphoproliferative syndrome. Curr Opin Rheumatol 15(4):417–421PubMedCrossRefGoogle Scholar
  93. 93.
    Su HC, Lenardo MJ (2008) Genetic defects of apoptosis and primary immunodeficiency. Immunol Allergy Clin North Am 28(2):329–351, ixPubMedCrossRefGoogle Scholar
  94. 94.
    Carter LB, Procter JL, Dale JK, Straus SE, Cantilena CC (2000) Description of serologic features in autoimmune lymphoproliferative syndrome. Transfusion 40(8):943–948PubMedCrossRefGoogle Scholar
  95. 95.
    Campagnoli MF, Garbarini L, Quarello P, Garelli E, Carando A, Baravalle V, Doria A, Biava A, Chiocchetti A, Rosolen A, Dufour C, Dianzani U, Ramenghi U (2006) The broad spectrum of autoimmune lymphoproliferative disease: molecular bases, clinical features and long-term follow-up in 31 patients. Haematologica 91(4):538–541PubMedGoogle Scholar
  96. 96.
    Su HC, de Oliveira JB, Leonardo MJ (2008) Programmed cell death in lymphocytes. In: Rich RR, Shearer WT, Fleisher TA, Schroeder H, Weyand C, Frew AJ (eds) Clinical immunology: principles and practice, 3rd edn. Mosby, PhiladelphiaGoogle Scholar
  97. 97.
    Puck JM, Rieux-Laucat F, Deist FL, Straus SE (2007) Autoimmune lymphoproliferative syndrome. In: Ochs HD, Smith CID, Puck JM (eds) Primary immunodeficiency diseases, a molecular and genetic approach, 2nd edn. Oxford University Press, New York, pp 326–341Google Scholar
  98. 98.
    Bleesing JJ, Straus SE, Fleisher TA (2000) Autoimmune lymphoproliferative syndrome. A human disorder of abnormal lymphocyte survival. Pediatr Clin North Am 47(6):1291–1310PubMedCrossRefGoogle Scholar
  99. 99.
    Kasahara Y, Wada T, Niida Y, Yachie A, Seki H, Ishida Y, Sakai T, Koizumi F, Koizumi S, Miyawaki T, Taniguchi N (1998) Novel FAS (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. Int Immunol 10(2):195–202PubMedCrossRefGoogle Scholar
  100. 100.
    Oliveira JB, Bidere N, Niemela JE, Zheng L, Sakai K, Nix CP, Danner RL, Barb J, Munson PJ, Puck JM, Dale J, Straus SE, Fleisher TA, Lenardo MJ (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA 104(21):8953–8958PubMedCrossRefGoogle Scholar
  101. 101.
    Husebye ES, Perheentupa J, Rautemaa R, Kampe O (2009) Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J Intern Med 265(5):514–529PubMedCrossRefGoogle Scholar
  102. 102.
    Kumar PG, Laloraya M, She JX (2002) Population genetics and functions of the autoimmune regulator (AIRE). Endocrinol Metab Clin North Am 31(2):321–338, viPubMedCrossRefGoogle Scholar
  103. 103.
    Meager A, Visvalingam K, Peterson P, Moll K, Murumagi A, Krohn K, Eskelin P, Perheentupa J, Husebye E, Kadota Y, Willcox N (2006) Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 3(7):e289PubMedCrossRefGoogle Scholar
  104. 104.
    Shikama N, Nusspaumer G, Hollander GA (2009) Clearing the AIRE: on the pathophysiological basis of the autoimmune polyendocrinopathy syndrome type-1. Endocrinol Metab Clin North Am 38(2):273–288, viiPubMedCrossRefGoogle Scholar
  105. 105.
    Suzuki E, Kobayashi Y, Kawano O, Endo K, Haneda H, Yukiue H, Sasaki H, Yano M, Maeda M, Fujii Y (2008) Expression of AIRE in thymocytes and peripheral lymphocytes. Autoimmunity 41(2):133–139PubMedCrossRefGoogle Scholar
  106. 106.
    Rautemaa R, Hietanen J, Niissalo S, Pirinen S, Perheentupa J (2007) Oral and oesophageal squamous cell carcinoma – a complication or component of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS-I). Oral Oncol 43(6):607–613PubMedCrossRefGoogle Scholar
  107. 107.
    Purtilo DT, Cassel CK, Yang JP, Harper R (1975) X-linked recessive progressive combined variable immunodeficiency (Duncan’s disease). Lancet 1(7913):935–940PubMedCrossRefGoogle Scholar
  108. 108.
    Marodi L, Notarangelo LD (2007) Immunological and genetic bases of new primary immunodeficiencies. Nat Rev Immunol 7(11):851–861PubMedCrossRefGoogle Scholar
  109. 109.
    Sumegi J, Seemayer TA, Huang D, Davis JR, Morra M, Gross TG, Yin L, Romco G, Klein E, Terhorst C, Lanyi A (2002) A spectrum of mutations in SH2D1A that causes X-linked ­lymphoproliferative disease and other Epstein-Barr virus-associated illnesses. Leuk Lymphoma 43(6):1189–1201PubMedCrossRefGoogle Scholar
  110. 110.
    Brandau O, Schuster V, Weiss M, Hellebrand H, Fink FM, Kreczy A, Friedrich W, Strahm B, Niemeyer C, Belohradsky BH, Meindl A (1999) Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet 8(13):2407–2413PubMedCrossRefGoogle Scholar
  111. 111.
    Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM, Okano M, Lanyi A, Sumegi J (1995) X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 38(4):471–478PubMedCrossRefGoogle Scholar
  112. 112.
    Benoit L, Wang X, Pabst HF, Dutz J, Tan R (2000) Defective NK cell activation in X-linked lymphoproliferative disease. J Immunol 165(7):3549–3553PubMedGoogle Scholar
  113. 113.
    Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, van Schaik S, Notarangelo L, Geha R, Roncarolo MG, Oettgen H, De Vries JE, Aversa G, Terhorst C (1998) The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395(6701):462–469PubMedCrossRefGoogle Scholar
  114. 114.
    Sumegi J, Huang D, Lanyi A, Davis JD, Seemayer TA, Maeda A, Klein G, Seri M, Wakiguchi H, Purtilo DT, Gross TG (2000) Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 96(9):3118–3125PubMedGoogle Scholar
  115. 115.
    Erdos M, Uzvolgyi E, Nemes Z, Torok O, Rakoczi E, Went-Sumegi N, Sumegi J, Marodi L (2005) Characterization of a new disease-causing mutation of SH2D1A in a family with X-linked lymphoproliferative disease. Hum Mutat 25(5):506PubMedCrossRefGoogle Scholar
  116. 116.
    Lindsten T, Seeley JK, Ballow M, Sakamoto K, St Onge S, Yetz J, Aman P, Purtilo DT (1982) Immune deficiency in the X-linked lymphoproliferative syndrome. II. Immunoregulatory T cell defects. J Immunol 129(6):2536–2540PubMedGoogle Scholar
  117. 117.
    Pasquier B, Yin L, Fondaneche MC, Relouzat F, Bloch-Queyrat C, Lambert N, Fischer A, de Saint-Basile G, Latour S (2005) Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med 201(5):695–701PubMedCrossRefGoogle Scholar
  118. 118.
    Yasuda N, Lai PK, Rogers J, Purtlo DT (1991) Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease. Clin Exp Immunol 83(1):10–16PubMedCrossRefGoogle Scholar
  119. 119.
    Purtilo DT, Grierson HL, Davis JR, Okano M (1991) The X-linked lymphoproliferative disease: from autopsy toward cloning the gene 1975-1990. Pediatr Pathol 11(5):685–710PubMedCrossRefGoogle Scholar
  120. 120.
    Migliorati R, Castaldo A, Russo S, Porta F, Fiorillo A, Guida S, Poggi V, Guarino A (1994) Treatment of EBV-induced lymphoproliferative disorder with epipodophyllotoxin VP16-213. Acta Paediatr 83(12):1322–1325PubMedCrossRefGoogle Scholar
  121. 121.
    Aghamohammadi A, Lougaris V, Plebani A, Miyawaki T, Durandy A, Hammarström L (2008) Predominantly antibody deficiencies. In: Rezaei N, Aghamohammadi A, Notarangelo LD (eds) Primary immunodeficiency diseases. Springer, Berlin/Heidelberg, pp 97–130CrossRefGoogle Scholar
  122. 122.
    Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, Cahn AP, Durham J, Heath P, Wray P, Pavitt R, Wilkinson J, Leversha M, Huckle E, Shaw-Smith CJ, Dunham A, Rhodes S, Schuster V, Porta G, Yin L, Serafini P, Sylla B, Zollo M, Franco B, Bolino A, Seri M, Lanyi A, Davis JR, Webster D, Harris A, Lenoir G, de Basile St G, Jones A, Behloradsky BH, Achatz H, Murken J, Fassler R, Sumegi J, Romeo G, Vaudin M, Ross MT, Meindl A, Bentley DR (1998) Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 20(2):129–135PubMedCrossRefGoogle Scholar
  123. 123.
    Latour S, Veillette A (2003) Molecular and immunological basis of X-linked lymphoproliferative disease. Immunol Rev 192:212–224PubMedCrossRefGoogle Scholar
  124. 124.
    Gilmour KC, Cranston T, Jones A, Davies EG, Goldblatt D, Thrasher A, Kinnon C, Nichols KE, Gaspar HB (2000) Diagnosis of X-linked lymphoproliferative disease by analysis of SLAM-associated protein expression. Eur J Immunol 30(6):1691–1697PubMedCrossRefGoogle Scholar
  125. 125.
    Shinozaki K, Kanegane H, Matsukura H, Sumazaki R, Tsuchida M, Makita M, Kimoto Y, Kanai R, Tsumura K, Kondoh T, Moriuchi H, Miyawaki T (2002) Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection. Int Immunol 14(10):1215–1223PubMedCrossRefGoogle Scholar
  126. 126.
    Rigaud S, Fondaneche MC, Lambert N, Pasquier B, Mateo V, Soulas P, Galicier L, Le Deist F, Rieux-Laucat F, Revy P, Fischer A, de Basile Saint G, Latour S (2006) XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444(7115):110–114PubMedCrossRefGoogle Scholar
  127. 127.
    Marsh RA, Villanueva J, Zhang K, Snow AL, Su HC, Madden L, Mody R, Kitchen B, Marmer D, Jordan MB, Risma KA, Filipovich AH, Bleesing JJ (2009) A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom 76(5):334–344PubMedGoogle Scholar
  128. 128.
    Henter JI, Samuelsson-Horne A, Arico M, Egeler RM, Elinder G, Filipovich AH, Gadner H, Imashuku S, Komp D, Ladisch S, Webb D, Janka G (2002) Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100(7):2367–2373PubMedCrossRefGoogle Scholar
  129. 129.
    Milone MC, Tsai DE, Hodinka RL, Silverman LB, Malbran A, Wasik MA, Nichols KE (2005) Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood 105(3):994–996PubMedCrossRefGoogle Scholar
  130. 130.
    Amrolia P, Gaspar HB, Hassan A, Webb D, Jones A, Sturt N, Mieli-Vergani G, Pagliuca A, Mufti G, Hadzic N, Davies G, Veys P (2000) Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood 96(4):1239–1246PubMedGoogle Scholar
  131. 131.
    Cunningham-Rundles C, Bodian C (1999) Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 92(1):34–48PubMedCrossRefGoogle Scholar
  132. 132.
    Howie D, Sayos J, Terhorst C, Morra M (2000) The gene defective in X-linked lymphoproliferative disease controls T cell dependent immune surveillance against Epstein-Barr virus. Curr Opin Immunol 12(4):474–478PubMedCrossRefGoogle Scholar
  133. 133.
    Aghamohammadi A, Kanegane H, Moein M, Farhoudi A, Pourpak Z, Movahedi M, Gharagozlou M, Zargar AA, Miyawaki T (2003) Identification of an SH2D1A mutation in a hypogammaglobulinemic male patient with a diagnosis of common variable immunodeficiency. Int J Hematol 78(1):45–47PubMedCrossRefGoogle Scholar
  134. 134.
    Soresina A, Lougaris V, Giliani S, Cardinale F, Armenio L, Cattalini M, Notarangelo LD, Plebani A (2002) Mutations of the X-linked lymphoproliferative disease gene SH2D1A mimicking common variable immunodeficiency. Eur J Pediatr 161(12):656–659PubMedCrossRefGoogle Scholar
  135. 135.
    Engel P, Eck MJ, Terhorst C (2003) The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol 3(10):813–821PubMedCrossRefGoogle Scholar
  136. 136.
    Mroczek EC, Weisenburger DD, Grierson HL, Markin R, Purtilo DT (1987) Fatal infectious mononucleosis and virus-associated hemophagocytic syndrome. Arch Pathol Lab Med 111(6):530–535PubMedGoogle Scholar
  137. 137.
    Hugle B, Suchowerskyj P, Hellebrand H, Adler B, Borte M, Sack U, Overberg-Schmidt US, Strnad N, Otto J, Meindl A, Schuster V (2004) Persistent hypogammaglobulinemia following mononucleosis in boys is highly suggestive of X-linked lymphoproliferative disease – report of three cases. J Clin Immunol 24(5):515–522PubMedCrossRefGoogle Scholar
  138. 138.
    Harrington DS, Weisenburger DD, Purtilo DT (1987) Malignant lymphoma in the X-linked lymphoproliferative syndrome. Cancer 59(8):1419–1429PubMedCrossRefGoogle Scholar
  139. 139.
    Gaspar HB, Sharifi R, Gilmour KC, Thrasher AJ (2002) X-linked lymphoproliferative disease: clinical, diagnostic and molecular perspective. Br J Haematol 119(3):585–595PubMedCrossRefGoogle Scholar
  140. 140.
    Dutz JP, Benoit L, Wang X, Demetrick DJ, Junker A, de Sa D, Tan R (2001) Lymphocytic vasculitis in X-linked lymphoproliferative disease. Blood 97(1):95–100PubMedCrossRefGoogle Scholar
  141. 141.
    Yin L, Ferrand V, Lavoue MF, Hayoz D, Philippe N, Souillet G, Seri M, Giacchino R, Castagnola E, Hodgson S, Sylla BS, Romeo G (1999) SH2D1A mutation analysis for diagnosis of XLP in typical and atypical patients. Hum Genet 105(5):501–505PubMedCrossRefGoogle Scholar
  142. 142.
    Chung B, Aoukaty A, Dutz J, Terhorst C, Tan R (2005) Signaling lymphocytic activation molecule-associated protein controls NKT cell functions. J Immunol 174(6):3153–3157PubMedGoogle Scholar
  143. 143.
    Purtilo DT (1986) Prevention and treatment of Epstein-Barr virus (EBV)-associated lymphoproliferative diseases in immune deficient patients. AIDS Res 2(Suppl 1):S177–181PubMedGoogle Scholar
  144. 144.
    Schwartzberg PL, Mueller KL, Qi H, Cannons JL (2009) SLAM receptors and SAP influence lymphocyte interactions, development and function. Nat Rev Immunol 9(1):39–46PubMedCrossRefGoogle Scholar
  145. 145.
    Ferguson PJ, Blanton SH, Saulsbury FT, McDuffie MJ, Lemahieu V, Gastier JM, Francke U, Borowitz SM, Sutphen JL, Kelly TE (2000) Manifestations and linkage analysis in X-linked autoimmunity-immunodeficiency syndrome. Am J Med Genet 90(5):390–397PubMedCrossRefGoogle Scholar
  146. 146.
    Slatter MA, Bhattacharya A, Abinun M, Flood TJ, Cant AJ, Gennery AR (2005) Outcome of boost haemopoietic stem cell transplant for decreased donor chimerism or graft dysfunction in primary immunodeficiency. Bone Marrow Transplant 35(7):683–689PubMedCrossRefGoogle Scholar
  147. 147.
    Williams LL, Rooney CM, Conley ME, Brenner MK, Krance RA, Heslop HE (1993) Correction of Duncan’s syndrome by allogeneic bone marrow transplantation. Lancet 342(8871):587–588PubMedCrossRefGoogle Scholar
  148. 148.
    Ziegner UH, Ochs HD, Schanen C, Feig SA, Seyama K, Futatani T, Gross T, Wakim M, Roberts RL, Rawlings DJ, Dovat S, Fraser JK, Stiehm ER (2001) Unrelated umbilical cord stem cell transplantation for X-linked immunodeficiencies. J Pediatr 138(4):570–573PubMedCrossRefGoogle Scholar
  149. 149.
    Gross TG, Filipovich AH, Conley ME, Pracher E, Schmiegelow K, Verdirame JD, Vowels M, Williams LL, Seemayer TA (1996) Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. Bone Marrow Transplant 17(5):741–744PubMedGoogle Scholar
  150. 150.
    Ochs HD, Oukka M, Torgerson TR (2009) TH17 cells and regulatory T cells in primary immunodeficiency diseases. J Allergy Clin Immunol 123(5):977–983, quiz 984–985PubMedCrossRefGoogle Scholar
  151. 151.
    Chatila TA (2005) Role of regulatory T cells in human diseases. J Allergy Clin Immunol 116(5):949–959, quiz 960PubMedCrossRefGoogle Scholar
  152. 152.
    Torgerson TR, Linane A, Moes N, Anover S, Mateo V, Rieux-Laucat F, Hermine O, Vijay S, Gambineri E, Cerf-Bensussan N, Fischer A, Ochs HD, Goulet O, Ruemmele FM (2007) Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene. Gastroenterology 132(5):1705–1717PubMedCrossRefGoogle Scholar
  153. 153.
    Wildin RS, Smyk-Pearson S, Filipovich AH (2002) Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet 39(8):537–545PubMedCrossRefGoogle Scholar
  154. 154.
    Halabi-Tawil M, Ruemmele FM, Fraitag S, Rieux-Laucat F, Neven B, Brousse N, De Prost Y, Fischer A, Goulet O, Bodemer C (2009) Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Br J Dermatol 160(3):645–651PubMedCrossRefGoogle Scholar
  155. 155.
    Gambineri E, Torgerson TR, Ochs HD (2003) Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 15(4):430–435PubMedCrossRefGoogle Scholar
  156. 156.
    De Benedetti F, Insalaco A, Diamanti A, Cortis E, Muratori F, Lamioni A, Carsetti R, Cusano R, De Vito R, Perroni L, Gambarara M, Castro M, Bottazzo GF, Ugazio AG (2006) Mechanistic associations of a mild phenotype of immunodysregulation, polyendocrinopathy, enteropathy, x-linked syndrome. Clin Gastroenterol Hepatol 4(5):653–659PubMedCrossRefGoogle Scholar
  157. 157.
    Wildin RS, Freitas A (2005) IPEX and FOXP3: clinical and research perspectives. J Autoimmun 25(Suppl):56–62PubMedCrossRefGoogle Scholar
  158. 158.
    Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, Bowcock AM (2000) JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 106(12):R75–81PubMedCrossRefGoogle Scholar
  159. 159.
    Lucas KG, Ungar D, Comito M, Bayerl M, Groh B (2007) Submyeloablative cord blood transplantation corrects clinical defects seen in IPEX syndrome. Bone Marrow Transplant 39(1):55–56PubMedCrossRefGoogle Scholar
  160. 160.
    Ozcan E, Notarangelo LD, Geha RS (2008) Primary immune deficiencies with aberrant IgE production. J Allergy Clin Immunol 122(6):1054–1062, quiz 1063–1064PubMedCrossRefGoogle Scholar
  161. 161.
    Whitelaw DA, Gopal R, Freeman V (2005) Survival of patients with SLE admitted to an intensive care unit-a retrospective study. Clin Rheumatol 24(3):223–227PubMedCrossRefGoogle Scholar
  162. 162.
    Zandman-Goddard G, Shoenfeld Y (2005) Infections and SLE. Autoimmunity 38(7):473–485PubMedCrossRefGoogle Scholar
  163. 163.
    Chou NK, Ko WJ, Chi NH, Chen YS, Yu HY, Hsu RB, Fang CT, Chang SC, Lin FY, Chu SH, Wang SS (2006) Sparing immunosuppression in heart transplant recipients with severe sepsis. Transplant Proc 38(7):2145–2146PubMedCrossRefGoogle Scholar
  164. 164.
    Taylor JL, Palmer SM (2006) Critical care perspective on immunotherapy in lung transplantation. J Intensive Care Med 21(6):327–344PubMedCrossRefGoogle Scholar
  165. 165.
    Taddio A, Faleschini E, Valencic E, Granzotto M, Tommasini A, Lepore L, Andolina M, Barbi E, Ventura A (2007) Medium-term survival without haematopoietic stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy. Eur J Pediatr 166(11):1195–1197PubMedCrossRefGoogle Scholar
  166. 166.
    Kobayashi I, Nakanishi M, Okano M, Sakiyama Y, Matsumoto S (1995) Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy. Eur J Pediatr 154(7):594–595PubMedCrossRefGoogle Scholar
  167. 167.
    Baud O, Goulet O, Canioni D, Le Deist F, Radford I, Rieu D, Dupuis-Girod S, Cerf-Bensussan N, Cavazzana-Calvo M, Brousse N, Fischer A, Casanova JL (2001) Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 344(23):1758–1762PubMedCrossRefGoogle Scholar
  168. 168.
    Mazzolari E, Forino C, Fontana M, D’Ippolito C, Lanfranchi A, Gambineri E, Ochs H, Badolato R, Notarangelo LD (2005) A new case of IPEX receiving bone marrow transplantation. Bone Marrow Transplant 35(10):1033–1034PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Shinsaku Imashuku
    • 1
  • Melinda Erdős
    • 2
  • Waleed Al-Herz
    • 3
  • Mohammad Hassan Bemanian
    • 4
  • Hirokazu Kanegane
    • 5
  • László Maródi
    • 2
  • Payam Mohammadinejad
    • 6
  • Sergio D. Rosenzweig
    • 7
  • Asghar Aghamohammadi
    • 8
  1. 1.Division of PediatricsTakasago-seibu HospitalTakasagoJapan
  2. 2.Department of Infectious and Pediatric ImmunologyMedical and Health Science Center, University of DebrecenDebrecenHungary
  3. 3.Department of PediatricsKuwait UniversityKuwaitKuwait
  4. 4.Department of Allergy and Clinical ImmunologyYazd University of Medical SciencesYazdIran
  5. 5.Department of PediatricsGraduate School of Medicine and Pharmaceutical, University of ToyamaToyamaJapan
  6. 6.Department of PediatricsResearch Center for Immunodeficiencies, Children’s Medical Center Hospital, Tehran University of Medical SciencesTehranIran
  7. 7.Primary Immunodeficiency Clinic, Laboratory of Host DefensesNIAID, National Institute of HealthBethesdaUSA
  8. 8.Division of Clinical Immunology and AllergyResearch Center for Immunodeficiencies, Children’s Medical Center Hospital, Tehran University of Medical SciencesTehranIran

Personalised recommendations